clinical trial · NCT05178862
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Scynexis, Inc.·phase3·terminated·n = 68
Candidiasis, InvasiveCandidemiaSCY-078FluconazoleEchinocandin
brief summary
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
started
Aug 3, 2022
primary completion
Nov 7, 2025
completion
Dec 16, 2025
last updated
Dec 19, 2025
official title
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol